The facts on small-cell lung cancer, or SCLC, and non-small-cell lung cancer, or NSCLC, like symptoms, prognosis, treatment, and recovery.

Lung cancer is cancer that starts in the lungs. There are two main types of lung cancer: non-small cell lung cancer (NSCLC), which makes up 80 to 85 percent of lung cancers; and small cell lung ...

Below are survival statistics generated by the Lung Cancer Staging Project based on stage for 8,000 patients with small cell lung cancer. Image Credit: Kateryna Kon/Shutterstock.com Stage 1 ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC. Small Cell Lung Cancer (SCLC): Symptoms, Causes, Diagnosis ...

Non-small cell lung cancer: The overall five-year survival rate for large cell lung cancer is 22.8%; the overall five-year survival rate for squamous cell lung cancer is 25.2%.

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 ...

Small cell lung cancer (SCLC) is one of the most aggressive and lethal solid tumors, accounting for ~15% of the approximately 2.5 million patients diagnosed with lung cancer worldwide each year 1,2.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

Small cell lung cancer (SCLC) is relatively rare to begin with, accounting for 10% to 15% of all lung cancers, according to the American Cancer Society. And the newly discovered subtype accounts ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial ...